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Background: Histological typing of non-small cell lung cancer
(NSCLC) has an increasing clinical relevance due to the emerging
differences in medical treatment between squamous and nonsqua-
mous tumors. However, most NSCLCs are diagnosed in an ad-
vanced stage, and the diagnosis is often obtained exclusively by
cytology either exfoliative or following fine needle aspiration. We
investigated the accuracy of fine needle aspiration cytology (FNAC)
in NSCLC typing as compared with histology.
Methods: Over the period 2000–2009, 1182 transbronchial needle
aspirate or transthoracic needle aspirate samples were obtained from
patients with suspicious thoracic lesions. In 474 patients, a cytolog-
ical diagnosis of primary NSCLC was obtained, and 186 (39%) of
them (108 transbronchial needle aspirates and 78 transthoracic
needle aspirates) received a parallel or subsequent histologic diag-
nosis on endoscopic biopsy (112) or surgery (74).
Results: At cytology, 158 (85%) NSCLC cases were typed (89
adenocarcinoma and 69 squamous cell carcinoma), while 28 (15%)
were classified as NSCLC not otherwise specified. At histology, 183
(98%) cases were typed (109 adenocarcinoma, 69 squamous cell
carcinoma, 3 adenosquamous carcinoma, and 2 large cell carci-
noma), and only 3 (2%) were classified as NSCLC not otherwise
specified. Cytological and histological typing was concordant in 137
of 156 (88%) cases (K  0.755; p  0.001). The positive predictive
value of FNAC in typing NSCLC was 92% for adenocarcinoma and
82% for squamous cell carcinoma.
Conclusion: FNAC in expert hands is fairly accurate for typing
NSCLC and can be regarded as an acceptable procedure for diag-
nostic and medical treatment planning purposes in most NSCLC
cases, especially when more invasive approaches are unfeasible. In
poorly differentiated and doubtful cases, the use of ancillary tech-
niques, such as immunocytochemistry, may be required to improve
the diagnostic yield.
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Lung cancer is the leading cause of cancer death both inmen and in women worldwide.1 Non-small cell lung
cancer (NSCLC) accounts for about 80 to 85% of all lung
cancers and is classified according to the World Health
Organization criteria into three major types: adenocarcinoma
(50%), squamous cell carcinoma (30–35%), and large cell
carcinoma (5–10%).2
Historically, NSCLC typing has not been considered
relevant for treatment planning. Therefore, a significant pro-
portion of NSCLCs used to be reported as NSCLC not
otherwise specified (NSCLC-NOS), particularly on cytology
or small biopsy samples.
More recently, tumor histotype has emerged as a crit-
ical variable in clinical decision making.3 Prospective ran-
domized studies have shown that new chemotherapeutic (i.e.,
pemetrexed) and molecular-targeted agents (i.e., gefitinib,
erlotinib, and bevacizumab) may lead to improved results, as
compared with prior standard therapeutic options, in
nonsquamous advanced lung carcinoma.4–11 Therefore, there
is an increasing demand for pathologists to differentiate
between squamous and nonsquamous NSCLC tumors. As
most lung cancer patients present at diagnosis in an advanced
unresectable stage, small biopsies or cytological samples are
frequently the only available material for diagnosis.
Exfoliative cytology obtained at the time of bronchos-
copy significantly increases the sensitivity and accuracy of
the diagnosis of lung cancer, but the diagnostic yield is high
only for central and endobronchial lesions.12 Fine needle
aspiration cytology (FNAC), either transthoracic needle as-
piration (TTNA) or transbronchial needle aspiration (TBNA),
is often used for the diagnosis of peripheral lung nodules and
hilar-mediastinal lymph nodes. Small cell lung cancer and
NSCLC can be consistently and accurately diagnosed by
FNAC,13 whereas its role in correctly typing NSCLC tumors
is still debated.14
The aim of this study was to evaluate the accuracy of
FNAC in differentiating NSCLCs of squamous from
nonsquamous histology type.
*Medical Oncology Unit, †Pneumology Unit, and ‡Radiology Unit, University
Hospital of Parma, Parma; §Institute of Pathology, U.C.S.C. Policlinico A.
Gemelli, Rome; and Department of Pathology and Laboratory Medicine,
Section of Pathology, University Hospital of Parma, Parma, Italy.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Marcello Tiseo, MD, Medical Oncology Unit,
University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy.
E-mail: mtiseo@ao.pr.it
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0603-0489
Journal of Thoracic Oncology • Volume 6, Number 3, March 2011 489
PATIENTS AND METHODS
Patients and Study Design
Cases were derived from a single-institution database
of TBNA and TTNA samples performed for diagnostic pur-
poses in patients with a thoracic lesion. From 2000 to 2009,
a total of 1182 thoracic FNACs were performed: 708 cases
were not diagnosed as NSCLC (331 negative for neoplastic
cells, 114 small cell lung cancers, 76 metastatic lesions, 75
inadequate samples, 19 recurrences of primary lung cancer,
17 lymphomas, 14 carcinoids, 14 mesenchymal tumors, and
48 others), while 474 cases yielded a cytologic diagnosis of
NSCLC, with or without an indication of a specific histotype.
Among these, 186 cases had a concurrent or subsequent
histological diagnosis and were considered for the study. All
cytological and histological slides were retrieved and re-
viewed for the study in a blinded fashion.
Cytological Diagnosis
TBNA was performed in patients with hilar-mediastinal
lymph nodes or submucosal and/or peribronchial lesions
using a 22-gauge needle connected to a flexible bronchovid-
eoscope. Computed tomography-guided TTNA was per-
formed in patients with peripheral nodules using a 22-gauge
needle connected to a pistol for aspiration. Both these proce-
dures were performed with rapid on-site examination of
specimens for evaluating the adequacy of sampling. The
smears were stained with May-Grunwald-Giemsa staining
plus Papanicolaou and/or periodic acid-Schiff (PAS) stain-
ings based on morphology and examined by two experienced
cytologists (R.N., A.G.). Differential diagnosis between squa-
mous and nonsquamous tumors was based on the criteria
detailed in Table 1.15,16 The cytologists reviewed the 186
cases independently from the pathologists who evaluated the
histology (G.R., E.M.S.) and without any knowledge of their
diagnosis. Discrepant interpretations between the cytologists
were resolved by consensus.
Histological Diagnosis
Histological samples included 74 surgical resections
and 112 endoscopic biopsies. Histology was evaluated on
standard Hematoxylin and Eosin (H&E) and PAS-Alcians
stains in all specimens. All cases were independently re-
viewed by two experienced pathologists (G.R., E.M.S.)
blinded to the original diagnosis. Discrepant interpretations
were observed only for small endoscopic biopsies and were
resolved by consensus or with the aid of immunostains. All
cases labeled as NSCLC-NOS in the original diagnoses were
immunostained.
A panel of immunohistochemical (IHC) markers was
used, including TTF-1 (thyroid transcription factor-1), CK-7
(cytokeratin-7), HMW-CKs (high-molecular-weight cytoker-
atins), and p63, according to standard procedures. TTF-1/
CK-7 positive and HMW-CKs/p63 negative cases were con-
sidered consistent with adenocarcinoma, whereas the
complementary staining pattern favored a squamous cell
carcinoma. Divergent or unreliable immunostaining results
were not considered for the diagnosis that was exclusively
based on morphology.
Statistical Analysis
The diagnostic agreement between cytology and histol-
ogy was calculated as the ratio of concordant cases to total
cases. Kappa statistics was used to assess the level of agree-
ment; Kappa values ranging from 0.61 to 0.8 were assumed
to indicate a very good agreement. Statistical significance
was considered for p values 0.05.
RESULTS
One hundred eighty-six FNAC cases (108 TBNAs
and 78 TTNAs) diagnosed as NSCLC, having a paired
concomitant or subsequent histologic diagnosis on endo-
scopic biopsies (112) or surgical specimen (74), were
included into the study.
FNAC allowed tumor typing in 158 cases (85%), 89
(56%) adenocarcinomas and 69 (44%) squamous cell carci-
nomas. Twenty-eight cases (15%) were diagnosed as
NSCLC-NOS because cytological features of a specific his-
totype could not be identified (Table 2). Cytological diagno-
sis was performed in 58 cases on slides with May-Grunwald-
Giemsa routine staining, while 39 cases had also
Papanicolaou staining, 65 PAS, and 24 both of them.
TABLE 1. Morphological Criteria Used on Fine Needle
Aspiration Cytological Samples for Differentiating Between
Adenocarcinoma and Squamous Cell Lung Carcinoma15,16
Adenocarcinoma
Squamous Cell
Carcinoma
Background Cell debris, foamy
macrophages
Necrosis
Cell distribution Small aggregates Individually dispersed
(in the background)
Architecture Glandular, acinar,
papillary
Solid, trabecular
Cells groups Morulae Pearl formations
Cell membrane Poorly defined Well defined
Cytoplasm Scanty, vacuolated Large, dense, keratinized
Nuclei Round-oval,
lightly stained
Irregular, hyperchromatic
Nucleoli Prominent (well
differentiated)
Inconspicuous
(keratinized) prominent
(nonkeratinized)
Nuclear pseudoinclusions Present Absent
TABLE 2. Distribution of NSCLC Typing Diagnosis
Cytology Histology
Adenocarcinoma 89 (56) 109 (59)
Squamous cell carcinoma 69 (44) 69 (38)
Large cell carcinoma — 2 (1)
Adenosquamous carcinoma — 3 (2)
Total 158 (85) 183 (98)
NSCLC-NOS 28 (15) 3 (2)
Values are given as n (%). A total of 186 patients had cytological and histological
diagnosis of NSCLC.
NSCLC-NOS, non-small cell lung cancer not otherwise specified.
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At histology, 183 cases (98%) were typed: 109 (59%)
adenocarcinomas, 69 (38%) squamous cell carcinomas, 3
(2%) adenosquamous, and 2 (1%) large cell carcinomas
(Table 2). Immunostains were performed in 40 (22%) endo-
scopic specimens, including all cases originally labeled as
NSCLC-NOS and cases with discordant cytological and his-
tological diagnoses. Immunostains allowed tumor typing in
28 cases. In nine other cases, the IHC profile was not
consistent with a specific histotype or was poorly interpret-
able and typing was based on morphology. At the end, only
three (2%) cases were considered as NSCLC-NOS mainly
due to limited or necrotic tissue.
Cytological and histological diagnoses were pair-
matched to obtain agreement estimates. The comparison
between cytological and histological corresponding types was
feasible in 156 cases, excluding 29 cases reported as NSCLC-
NOS (28 cases by cytology and 3 by histology, 2 of which
were NOS by both methods) and one case diagnosed as
adenosquamous carcinoma at histology (Table 3). Notably,
one case classified as NSCLC-NOS at histology had been
identified as squamous carcinoma at cytology; the main
reason for this peculiar result can be ascribed to the lack of
cellular material on the small biopsy and the evidence of
abundant dense cytoplasm without glandular formation on the
cytologic smear.
Agreement between cytological and histological typing
was found in 137 of 156 (88%) cases (K 0.755; p 0.001).
Concordant diagnoses included 55 squamous cell carcinomas
and 82 adenocarcinomas (Table 4). Twelve cases classified as
squamous cell carcinoma at cytology were diagnosed as
adenocarcinoma at histology (Figures 1A, B; Tables 3 and 4),
whereas seven cases classified as adenocarcinoma at cytology
resulted squamous cell carcinoma at histology (Figures 2A, B;
Tables 3 and 4). Of the 28 NSCLC-NOS cases at cytology,
histologic typing was obtained in 26 cases, 9 of which with
the aid of IHC (Table 3).
Positive predictive value of FNAC in NSCLC typing
was 92% (82 of 89) for adenocarcinomas and 82% (55 of 67)
for squamous cell carcinomas (Table 4). Sensitivity, speci-
ficity, and positive and negative predictive values of cytology
for a diagnosis of adenocarcinomas were 87%, 89%, 92%,
and 82%, respectively.
DISCUSSION
For clinical purposes, lung cancer has been historically
classified into small cell and non-small cell types; this time-
honored practice is no longer tenable, given the advent of
new drugs with indications to specific NSCLC types.4–11
Differentiating between squamous and nonsquamous
tumors may be challenging when limited material is available
such as in FNAC samples or in bronchoscopic biopsies.
However, as only 25 to 30% of tumors are resected, these
types of specimen represent the source of tissue diagnosis in
most patients.16,17 In this setting, the issue of accuracy of the
cytological diagnosis is critical.
Several studies have addressed the diagnostic agree-
ment between endoscopic biopsies and resection specimens
and have provided reassuring figures of concordance for most
histotypes.17–20 The literature is scarcer when it comes to the
accuracy of cytology.14,21,22
The results of this study indicate that FNAC allows
typing of NSCLCs with high accuracy, considering the agree-
ment with histology (88%) and the positive predictive value
for squamous and nonsquamous histotype (82% and 92%,
respectively). These figures compare favorably with those
reported in similar studies that indicated a value of 45%17 and
60%.21 In our series, the accuracy of FNAC may be espe-
cially high due to the experience of the cytologists and their
habitude to work in a multidisciplinary team.
The diagnostic yield of FNAC should be compared
with that of the corresponding histology that allowed typing
in 98% of cases in the study. The high proportion (40%) of
surgical specimens included in the series and the use of IHC
staining to aid in the morphological interpretation are likely
explanation for these results. It should also be considered that
for the purpose of the study, the pathologists were asked to
express a judgment on the NSCLC histotypes also in the nine
cases in which the IHC profile was not entirely consistent or
was poorly interpretable. Adding the latter cases to the three
NSCLC-NOS, a 6% (12 of 186) proportion of NSCLC-NOS
is obtained that is consistent with a recent study on bronchial
biopsies.20
The reasons to explain discrepancies between cytolog-
ical and histological diagnosis (19 of 156 cases) are manifold.
Sampling bias and tumor heterogeneity are a likely cause for
the misdiagnosis of adenocarcinoma as squamous cell carci-
noma due to the failure of detecting keratinized cells. The
sampling or smearing techniques and the tumor necrosis may
also induce artifactual vacuolization or pseudoacinar struc-
tures that contribute to a proportion of misdiagnoses. Poor
cell differentiation with large eosinophylic cytoplasms, sheet-
like aggregation of cells, and necrosis are the most likely
causes of adenocarcinomas being diagnosed as squamous cell
TABLE 3. Cytological Diagnosis in 186 FNAs from NSCLC
with Corresponding Histological Diagnosis
Cytology/Histology SQC ADC LCC ADSQC NOS Total
SQC 55 12 — 1 1 69
ADC 7 82 — — — 89
NOS 7 15 2 2 2 28
Total 69 109 2 3 3 186
SQC, squamous cell carcinoma; ADC, adenocarcinoma; LCC, large cell carcinoma;
ADSQC, adenosquamous carcinoma; NOS, not otherwise specified.
TABLE 4. Comparison Between Cytological and
Histological Type Definition (Adenocarcinomas vs. Squamous
Tumors)
Cytology/Histology ADC SQC Total
ADC 82 7 89
SQC 12 55 67
Total 94 62 156
ADC, adenocarcinoma; SQC, squamous cell carcinoma.
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carcinomas. The same features are also challenging for diag-
nosis in small biopsy samples where IHC is most indicated.
Histology was considered as the gold standard; how-
ever, it should be acknowledged that its diagnostic reproduc-
ibility is suboptimal. Figures of interobserver agreement in
the diagnosis of squamous versus nonsquamous histology
using the 2004 World Health Organization criteria were
recently reported.23 In this study, 12 expert pulmonary pa-
thologists and 12 community pathologists were asked to
evaluate the same digital images from 96 primary NSCLC
resections. The K value for overall agreement among all
pathologists was 0.55, while for expert pathologists K 0.64
and for community pathologists K  0.41, evidencing a
relevant risk of misdiagnosis using morphology alone.
The diagnosis of large cell carcinoma deserves spe-
cific discussion as this is a controversial and likely heter-
ogeneous entity in terms of morphological and immuno-
phenotype features.16,24
To improve diagnostic accuracy of FNAC, especially in
poorly differentiated and doubtful tumors, it might be useful
to integrate morphology with validated ancillary techniques,
such as immunohistochemistry.16,25 An increasing number of
reports has addressed the use and validation of antibody
markers, such as TTF-1, CK-7, p63, HMW-CKs, and desmo-
collin-3, in the subtyping of NSCLCs.20,21,26,27
Khayyata et al. investigated a IHC panel made of
TTF-1, CK-7, CK-20, p63, and CK-5/6 in differentiating
NSCLC types from 53 FNA specimens compared with sur-
gical samples. Using only cytomorphologic criteria, the con-
cordance between cytologic and histologic diagnosis was
66% for adenocarcinoma and 53% for squamous cell carci-
noma but increased when IHC was included in the diagnostic
algorithm.21 Nicholson et al. showed that 53% of the cases
(17 of 32 small biopsies or cytological samples) were clas-
sified as NSCLC-NOS after the initial light microscopic
review, while after special stains (TTF-1, p63, CK-5/6, and
PAS), only 6 of the 32 (19%) remained unclassified.26
In conclusion, our data indicate that FNAC, in expert
hands, is fairly sensitive and accurate in typing NSCLCs and
can be regarded as an acceptable procedure for diagnosis and
treatment planning, especially when other more invasive
approaches are unfeasible. Poorly differentiated and doubtful
cases might benefit of ancillary techniques, such as validated
immunocytochemical panels, to refine type diagnosis. The role
of immunocytochemistry to improve sensitivity and accuracy of
conventional cytology should be further investigated.
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